cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.24658509.v1
title: Supplementary Material for: 3-Dimensional ultrastructural analysis of the rat pinealocyte; presence of secretory bulbous projections delineated from the cell body by junctional complexes.

description: Introduction: The superficial pineal gland of the Sprague Dawley rat is a neuroendocrine structure secreting the hormone melatonin. By use of block face scanning electron microscopy, our aim here was to identify the 3-dimensional ultrastructure of the gland. 
Methods: A series of 2,731 block face images of the rat pineal tissue, 30 nm in thickness, was obtained in a Teneo Video Volume scanning electron microscope and used for 3-dimensional reconstruction by use of the TrakEM2-plugin in the ImageJ software. Thin sections of the tissue were cut for transmission electron microscopy.
Results: Our analyses revealed cellular bulbous processes, containing 50 – 100 nm clear vesicles, that emerged from a neck-like area at the cell body of the pinealocyte. These bulbous processes extend into small canaliculi located in the center of parenchymal folliculi of the gland as well as into the perivascular spaces. Junctional complexes, comprising both gap and tight junctions, connected the lateral cellular membranes of the pinealocytes, where the bulbous processes emerged from the cell bodies. The canaliculi were via the extracellular space connected to the perivascular spaces. 
Discussion: The junctional complexes reported here would prevent a substance, released from the vesicles in the bulbous processes, from targeting the cell body from which they emerge. In line with previous combined morphological and biochemical demonstrations of glutamate located in clear vesicles of bulbous processes in the rat pineal gland, our ultrastructural data support the concept that bulbous processes could participate in a paracrine glutamatergic inhibition of the melatonin secretion in the pineal gland.
Conclusion: Bulbous secretory projections separated from the cell body by a junctional complex is a new feature of neuroendocrine cells.
DOI: 10.5281/zenodo.7389667
title: Screening tests for N sorption allow to select and engineer biochars for N mitigation during biomass processing

description: Csv and xlsx files:



	
Biochar_characteristics: Biochar characteristics including chemical analyses, NH3 and NH4 sorption. 
	
Ammonium_sorption_treatments: Effect of treatment on NH4 sorption + difference in NH4 sorption of feedstock and biochars made from it
	
Ammonia_sorption_treatments: Effect of treatment on NH3 sorption



Metadata can be found in the corresponding txt. files. 


R-scripts:



	
Gasmetingen_purebiochars_2021_NH3: calculation of the NH3 sorption
	
NH3_treatments: Effect of treatment on NH3 sorption
	
ARF_treatments: Effect of treatment on NH4 sorption
	
ARF: First data analysis (correlation)
	
ARF en NH3 sorptie ggplot: figures linear relationship between NH3 or NH4 sorption with chemical parameters
description: The Research Foundation - Flanders (FWO) has (co-)financed the research (BASTA, S000119N).
DOI: 10.5281/zenodo.7389668
title: Screening tests for N sorption allow to select and engineer biochars for N mitigation during biomass processing

description: Csv and xlsx files:



	
Biochar_characteristics: Biochar characteristics including chemical analyses, NH3 and NH4 sorption. 
	
Ammonium_sorption_treatments: Effect of treatment on NH4 sorption + difference in NH4 sorption of feedstock and biochars made from it
	
Ammonia_sorption_treatments: Effect of treatment on NH3 sorption



Metadata can be found in the corresponding txt. files. 


R-scripts:



	
Gasmetingen_purebiochars_2021_NH3: calculation of the NH3 sorption
	
NH3_treatments: Effect of treatment on NH3 sorption
	
ARF_treatments: Effect of treatment on NH4 sorption
	
ARF: First data analysis (correlation)
	
ARF en NH3 sorptie ggplot: figures linear relationship between NH3 or NH4 sorption with chemical parameters
description: The Research Foundation - Flanders (FWO) has (co-)financed the research (BASTA, S000119N).
DOI: 10.6084/m9.figshare.24906363
title: Supplementary Material for: Association of Programmed Cell Death 1 Inhibitor with Circumorificial Plasmacytosis

description: Introduction: The development of immune checkpoint inhibitors is considered one of the most important advances in cancer treatment. Pembrolizumab is an immune checkpoint inhibitor against programmed death 1 (PD-1) receptors that has demonstrated antineoplastic activity against various malignancies, including non-small cell lung cancer, melanoma, and triple-negative breast cancer. Pembrolizumab is associated with numerous adverse reactions including mucosal and cutaneous reactions referred to as immune-related adverse events. These events can impact patient quality of life, lead to dose reduction or discontinuation of the medication. A comprehensive understanding of pembrolizumab’s toxicities is crucial for the initiation of treatment. Case Presentation: We present the case of a 27-year-old man with stage IVB thymic carcinoma with a bulky anterior mediastinal mass, bilateral jugular, bilateral peri-tracheal, and bilateral cardiophrenic lymphadenopathy, and a small pericardial effusion. He received pembrolizumab IV every 3 weeks for 53 cycles over 39 months. The patient developed bleeding oral lesions approximately 38 months after treatment with pembrolizumab. Conclusion: The patient’s pembrolizumab treatment was not interrupted and the perioral rash ultimately improved after treatment with steroids.
DOI: 10.6084/m9.figshare.24906363.v1
title: Supplementary Material for: Association of Programmed Cell Death 1 Inhibitor with Circumorificial Plasmacytosis

description: Introduction: The development of immune checkpoint inhibitors is considered one of the most important advances in cancer treatment. Pembrolizumab is an immune checkpoint inhibitor against programmed death 1 (PD-1) receptors that has demonstrated antineoplastic activity against various malignancies, including non-small cell lung cancer, melanoma, and triple-negative breast cancer. Pembrolizumab is associated with numerous adverse reactions including mucosal and cutaneous reactions referred to as immune-related adverse events. These events can impact patient quality of life, lead to dose reduction or discontinuation of the medication. A comprehensive understanding of pembrolizumab’s toxicities is crucial for the initiation of treatment. Case Presentation: We present the case of a 27-year-old man with stage IVB thymic carcinoma with a bulky anterior mediastinal mass, bilateral jugular, bilateral peri-tracheal, and bilateral cardiophrenic lymphadenopathy, and a small pericardial effusion. He received pembrolizumab IV every 3 weeks for 53 cycles over 39 months. The patient developed bleeding oral lesions approximately 38 months after treatment with pembrolizumab. Conclusion: The patient’s pembrolizumab treatment was not interrupted and the perioral rash ultimately improved after treatment with steroids.
DOI: 10.5281/zenodo.10461565
title: Item Analysis in Multiple Choice Questions: A Study on Question Difficulty and Authors' Evaluation - DATASET

description: This dataset includes item analysis results of multiple-choice questions used in medical education assessement, as well as difficulty estimates provided by question authors regarding their respective questions.
DOI: 10.5281/zenodo.10461566
title: Item Analysis in Multiple Choice Questions: A Study on Question Difficulty and Authors' Evaluation - DATASET

description: This dataset includes item analysis results of multiple-choice questions used in medical education assessement, as well as difficulty estimates provided by question authors regarding their respective questions.
DOI: 10.6084/m9.figshare.24948186
title: Record table from camera trap survey in Baka hunting territories in south-eastern Cameroon

description: Camera trap record table of survey in Baka hunting areas - dates and locations are given in the camera trap files
DOI: 10.6084/m9.figshare.24893193
title: Supplementary Material for: Isolated Myeloid Sarcoma masquerading as scattered abscesses in a septic patient: A Case Report and Literature Review

description: Introduction: Myeloid sarcoma (MS) is also known as chloroma, extramedullary acute myeloid leukemia, or granulocytic sarcoma. MS is a rare extramedullary infiltration of myeloid cells most commonly collecting in the skin and causing a small number of localized lesions. It is strongly associated with acute myeloid leukemia (AML); however, MS more commonly occurs after diagnosis of AML is previously established or after previous treatment of AML. 
Case Presentation: This case describes a patient with an atypical presentation of myeloid sarcoma with no known history of AML and up to 18 lesions identified on CT scan that were previously being monitored for months by PCP. She presented with sepsis attributed to choledocholithiasis versus bacteremia from scattered abscesses versus osteomyelitis of her left knee; nonetheless, lactic acid failed to improve after CBD stent with biliary sphincterotomy/dilation or with I&D and empiric antibiotics. Core needle biopsy of her left abdominal sidewall was eventually positive for MS, but she unfortunately developed multiorgan failure with symptomatic hypercalcemia refractory to treatment and ultimately decided to go comfort care rather than pursue further workup and treatment. Although bone marrow biopsy was ultimately not performed to rule out synchronous AML, this is likely a case of isolated MS due to her scattered skin lesions being present for months prior to hospitalization and acute illness. 
Conclusion: This case highlights the importance of maintaining MS in the differential diagnosis and the importance of early diagnostic core needle biopsy for patients with persistent skin lesions of unknown origin.
DOI: 10.6084/m9.figshare.24893193.v1
title: Supplementary Material for: Isolated Myeloid Sarcoma masquerading as scattered abscesses in a septic patient: A Case Report and Literature Review

description: Introduction: Myeloid sarcoma (MS) is also known as chloroma, extramedullary acute myeloid leukemia, or granulocytic sarcoma. MS is a rare extramedullary infiltration of myeloid cells most commonly collecting in the skin and causing a small number of localized lesions. It is strongly associated with acute myeloid leukemia (AML); however, MS more commonly occurs after diagnosis of AML is previously established or after previous treatment of AML. 
Case Presentation: This case describes a patient with an atypical presentation of myeloid sarcoma with no known history of AML and up to 18 lesions identified on CT scan that were previously being monitored for months by PCP. She presented with sepsis attributed to choledocholithiasis versus bacteremia from scattered abscesses versus osteomyelitis of her left knee; nonetheless, lactic acid failed to improve after CBD stent with biliary sphincterotomy/dilation or with I&D and empiric antibiotics. Core needle biopsy of her left abdominal sidewall was eventually positive for MS, but she unfortunately developed multiorgan failure with symptomatic hypercalcemia refractory to treatment and ultimately decided to go comfort care rather than pursue further workup and treatment. Although bone marrow biopsy was ultimately not performed to rule out synchronous AML, this is likely a case of isolated MS due to her scattered skin lesions being present for months prior to hospitalization and acute illness. 
Conclusion: This case highlights the importance of maintaining MS in the differential diagnosis and the importance of early diagnostic core needle biopsy for patients with persistent skin lesions of unknown origin.
DOI: 10.6084/m9.figshare.24948201
title: Camera trap files

description: Camera trap file that is part of the survey which the associated record table is part - file gives dates and locations
DOI: 10.6084/m9.figshare.24948201.v1
title: Camera trap files

description: Camera trap file that is part of the survey which the associated record table is part - file gives dates and locations
DOI: 10.6084/m9.figshare.24925404
title: Supplementary Material for: Li-Fraumeni Syndrome with Unusual Type Related Malignancies: Case Report

description: Li-Fraumeni syndrome (LFS) is a rare autosomal dominant disorder brought on by pathogenic mutations in the TP53 tumor suppressor gene. It is characterized by a high lifetime risk of developing various cancers at a relatively young age. We are presenting a 48-year-old male with LFS that confirmed by genetic test triggered by leukemia diagnosis of his son this year. The main symptoms were abdominal pain & weight loss. Patient diagnosed recently by two synchronous primary tumors, gastric invasive Adenocarcinoma with MSI-high & low grade Well-differentiated pancreatic Neuroendocrine Tumor, not usually common type of cancers related to LFS. Our radiological assessment showed significant response in gastric cancer and stable disease in pancreatic neuroendocrine tumor after eight cycles of chemo-immunotherapy in form of (FOLFOX-Nivolumab). 
Gastric cancer & neuroendocrine tumor considered as unusual associated type of cancers related to LFS. Further exploration required to determine the appropriate clinical management especially in LFS patients who had a cancer with MSI-high status.
DOI: 10.6084/m9.figshare.24925404.v1
title: Supplementary Material for: Li-Fraumeni Syndrome with Unusual Type Related Malignancies: Case Report

description: Li-Fraumeni syndrome (LFS) is a rare autosomal dominant disorder brought on by pathogenic mutations in the TP53 tumor suppressor gene. It is characterized by a high lifetime risk of developing various cancers at a relatively young age. We are presenting a 48-year-old male with LFS that confirmed by genetic test triggered by leukemia diagnosis of his son this year. The main symptoms were abdominal pain & weight loss. Patient diagnosed recently by two synchronous primary tumors, gastric invasive Adenocarcinoma with MSI-high & low grade Well-differentiated pancreatic Neuroendocrine Tumor, not usually common type of cancers related to LFS. Our radiological assessment showed significant response in gastric cancer and stable disease in pancreatic neuroendocrine tumor after eight cycles of chemo-immunotherapy in form of (FOLFOX-Nivolumab). 
Gastric cancer & neuroendocrine tumor considered as unusual associated type of cancers related to LFS. Further exploration required to determine the appropriate clinical management especially in LFS patients who had a cancer with MSI-high status.
DOI: 10.6084/m9.figshare.24912534
title: Supplementary Material for: PATHOLOGICAL COMPLETE RESPONSE TO PEMBROLIZUMAB PLUS AXITINIB COMBINATION FOLLOWING SERIOUS IMMUNE-RELATED ADVERSE EVENTS IN AN ADVANCED RENAL CELL CARCINOMA PATIENT WITH A HISTORY OF RHEUMATOID ARTHRITIS

description: Introduction
Immune checkpoint inhibitors (ICIs)-based combinations have improved survival outcomes of advanced renal cell carcinoma (RCC) patients and are currently recommended as first-line treatment options. Rheumatoid arthritis (RA) is a systemic autoimmune disease (AD) of unknown etiology characterized by a chronic inflammatory process involving joints and extra-articular organs. Patients with AD are usually excluded from large randomized clinical trials investigating immunotherapeutic drugs. Therefore, little is known about clinical outcomes of patients with a history of RA treated with ICIs in real world practice. 
Case presentation
In the present paper we report the clinical outcome of an advanced RCC patient with a history of RA treated with pembrolizumab in combination with axitinib. The patient experienced serious immune-related adverse events (irAEs) and achieved pathological complete response following only one ICI administration. 
Conclusion
Our case report shows that ICI-based combinations can be administered efficaciously in advanced RCC patients with a history of AD. However, a close monitoring of these patients is required given the risk of irAEs and clinical exacerbations of symptoms associated with the preexisting AD. Moreover, prospective clinical data are needed to assess the hypothesis of a correlation between the onset of irAEs and AD flares and responses and survival outcomes to ICIs.
DOI: 10.6084/m9.figshare.24912534.v1
title: Supplementary Material for: PATHOLOGICAL COMPLETE RESPONSE TO PEMBROLIZUMAB PLUS AXITINIB COMBINATION FOLLOWING SERIOUS IMMUNE-RELATED ADVERSE EVENTS IN AN ADVANCED RENAL CELL CARCINOMA PATIENT WITH A HISTORY OF RHEUMATOID ARTHRITIS

description: Introduction
Immune checkpoint inhibitors (ICIs)-based combinations have improved survival outcomes of advanced renal cell carcinoma (RCC) patients and are currently recommended as first-line treatment options. Rheumatoid arthritis (RA) is a systemic autoimmune disease (AD) of unknown etiology characterized by a chronic inflammatory process involving joints and extra-articular organs. Patients with AD are usually excluded from large randomized clinical trials investigating immunotherapeutic drugs. Therefore, little is known about clinical outcomes of patients with a history of RA treated with ICIs in real world practice. 
Case presentation
In the present paper we report the clinical outcome of an advanced RCC patient with a history of RA treated with pembrolizumab in combination with axitinib. The patient experienced serious immune-related adverse events (irAEs) and achieved pathological complete response following only one ICI administration. 
Conclusion
Our case report shows that ICI-based combinations can be administered efficaciously in advanced RCC patients with a history of AD. However, a close monitoring of these patients is required given the risk of irAEs and clinical exacerbations of symptoms associated with the preexisting AD. Moreover, prospective clinical data are needed to assess the hypothesis of a correlation between the onset of irAEs and AD flares and responses and survival outcomes to ICIs.
DOI: 10.6084/m9.figshare.24906366
title: Supplementary Material for: Late presentation of pseudophakic macula edema from oral kinase inhibitors: A case series and literature review

description: Introduction: Two cases of late presentation ( &gt; five years ) of bilateral pseudophakic macula edema related to oral tyrosine kinase inhibitors are described. These cases are the first of their type in the published literature . A review of ocular inflammatory complications of tyrosine kinase inhibitors in the current literature is explored . 

Case Presentations(s): Case 1 is a 83 year old female who has been stable on Ibrutinib (Imbruvica®) for chronic lymphocytic leukemia (CLL) . She presented with bilateral blurred vision from severe cystoid macula edema , seven years following routine cataract surgery . She was treated with intravitreal steroids with complete resolution without relapse. Case 2 is a 76 year old female who was on therapy for polycythemia vera with Ruxolitinib (Jakafi®). She presented with bilateral blurred vision from mild cystoid macula edema , six years following routine cataract surgery. She responded well to topical steroids without relapse. In both cases oral tyrosine kinase inhibitor agents were presumed to be the underlying cause and were ceased. Over the last five years there have been increasing reports in the literature of the inflammatory effects of tyrosine kinase inhibitors on the retina , uvea and optic nerve.

 Conclusion: Late presentation of pseudophakic macula edema following routine cataract surgery is rare. Such presentations such should prompt investigation of chronic use of systemic medications especially oral kinase inhibitors. Patients who must remain on these agents require ongoing ophthalmologic assessment in view of their long-term inflammatory side effects.
DOI: 10.6084/m9.figshare.24906366.v1
title: Supplementary Material for: Late presentation of pseudophakic macula edema from oral kinase inhibitors: A case series and literature review

description: Introduction: Two cases of late presentation ( &gt; five years ) of bilateral pseudophakic macula edema related to oral tyrosine kinase inhibitors are described. These cases are the first of their type in the published literature . A review of ocular inflammatory complications of tyrosine kinase inhibitors in the current literature is explored . 

Case Presentations(s): Case 1 is a 83 year old female who has been stable on Ibrutinib (Imbruvica®) for chronic lymphocytic leukemia (CLL) . She presented with bilateral blurred vision from severe cystoid macula edema , seven years following routine cataract surgery . She was treated with intravitreal steroids with complete resolution without relapse. Case 2 is a 76 year old female who was on therapy for polycythemia vera with Ruxolitinib (Jakafi®). She presented with bilateral blurred vision from mild cystoid macula edema , six years following routine cataract surgery. She responded well to topical steroids without relapse. In both cases oral tyrosine kinase inhibitor agents were presumed to be the underlying cause and were ceased. Over the last five years there have been increasing reports in the literature of the inflammatory effects of tyrosine kinase inhibitors on the retina , uvea and optic nerve.

 Conclusion: Late presentation of pseudophakic macula edema following routine cataract surgery is rare. Such presentations such should prompt investigation of chronic use of systemic medications especially oral kinase inhibitors. Patients who must remain on these agents require ongoing ophthalmologic assessment in view of their long-term inflammatory side effects.
DOI: 10.6084/m9.figshare.24906429
title: Supplementary Material for: Orbital edema secondary to a sphenoidal mass as the presenting symptom of high-risk precursor B cell acute lymphoblastic leukemia: a case report

description: Introduction
Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy, known to present with ocular manifestations in rare cases. 

Case presentation
We describe the case of a 9-year-old previously healthy male who developed a 2-day history of periocular swelling and was found on MRI to have a large sphenoidal mass. Further work up showed involvement of the spinal cord, iliac crests, and kidneys. His initial blood work showed no hematological abnormalities. A bone marrow biopsy taken from the iliac crest demonstrated &gt;90% B lymphoblasts and flow cytometry was positive for CD19. Overall, his investigations were consistent with a diagnosis of precursor B cell ALL (pre B-ALL). His neuro-ophthalmic exam showed right sided subtle periocular edema, decreased palpebral fissure height, and proptosis. Posterior exam showed mild nasal elevation of the right optic disc without vessel obscuration and mild tortuosity of the peripheral vessels. He otherwise had no overt signs of afferent or efferent dysfunction despite the proximity of the mass to his optic nerve and globe. 

Conclusion
This case demonstrates that high risk pre B-ALL, a childhood cancer not commonly associated with orbital manifestations, can present with orbital edema and normal leukocyte count in an otherwise healthy child.